{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:23:30Z","timestamp":1770416610079,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18\u202fK07494"],"award-info":[{"award-number":["18\u202fK07494"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jneuroim.2018.09.012","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T06:52:38Z","timestamp":1538031158000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis"],"prefix":"10.1016","volume":"325","author":[{"given":"Kazuo","family":"Iwasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-5183","authenticated-orcid":false,"given":"Hiroaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2018.09.012_bb0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yexcr.2016.08.008","article-title":"Lactate induced HIF-1alpha-PRMT1 cross talk affects MHC I expression in monocytes","volume":"347","author":"Gupta","year":"2016","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0015","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0020","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1002\/eji.201646525","article-title":"Hypoxia augments MHC class I antigen presentation via facilitation of ERO1-alpha-mediated oxidative folding in murine tumor cells","volume":"46","author":"Kajiwara","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0025","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0030","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","article-title":"The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands","volume":"181","author":"Kinter","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/01.bor.0000179947.58271.9a","article-title":"Role of major histocompatibility complex class I molecules in autoimmune myositis","volume":"17","author":"Nagaraju","year":"2005","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0055","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3389\/fphar.2018.00536","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0065","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1096\/fj.03-0039fje","article-title":"Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies","volume":"17","author":"Wiendl","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2005.05.003","article-title":"Immunobiology of muscle: advances in understanding an immunological microenvironment","volume":"26","author":"Wiendl","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jneuroim.2018.09.012_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818303539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572818303539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:32:43Z","timestamp":1759048363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572818303539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":15,"alternative-id":["S0165572818303539"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.09.012","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2018.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}